The Genomics Core, established as part of a larger WSU Core (Applied Genomics Technology Center or AGTC), serves KCI members with state-of-the-art genomic technologies and expert consultation services. Core scientists interact with researchers at the design phase of projects and assist in incorporating genomics approaches by generating preliminary data, providing methodology descriptions, analyzing cost, and performing high throughput implementation of technology. The Genomics Core personnel work with the Biostatistics Core to incorporate seamless data management and bioinformatic and biostatistical analysis to genomic data generated by the Core. The Genomics Core is grouped in the Cross Disciplinary Core Cluster which, in addition to the Genomics Core, includes the Biostatistics, Biobanking and Correlative Sciences, and Pharmacology Cores. Standard services provided by the Genomics Core to the investigators include nucleic acid isolation, DNA sequencing including Sanger and Next Generation Sequencing, genotyping including both germline and somatic variations and methylation, and expression analysis. The Genomics Core contributed to 68 peer reviewed publications during the current review period. In October 2013, the Core was inspected by CAP/CLIA for certification of panels of lung actionable amplifications/deletions and oncogenes for clinical use. This allowed the Thoracic Oncology Group at KCI in collaboration with the Genomics Core to launch a clinical trial to evaluate the ability to initiate therapy in advanced NSCLC patients based on a comprehensive genomic analysis of their tumors. The primary objective is to define the percentage of patients who are able to start therapy based on the genomic analysis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA022453-37
Application #
9605746
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-12-01
Budget End
2019-11-30
Support Year
37
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Wayne State University
Department
Type
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
Herroon, Mackenzie K; Rajagurubandara, Erandi; Diedrich, Jonathan D et al. (2018) Adipocyte-activated oxidative and ER stress pathways promote tumor survival in bone via upregulation of Heme Oxygenase 1 and Survivin. Sci Rep 8:40
Colacino, Justin A; Azizi, Ebrahim; Brooks, Michael D et al. (2018) Heterogeneity of Human Breast Stem and Progenitor Cells as Revealed by Transcriptional Profiling. Stem Cell Reports 10:1596-1609
Blocker, Stephanie J; Shields, Anthony F (2018) Imaging of Nanoparticle Distribution to Assess Treatments That Alter Delivery. Mol Imaging Biol 20:340-351
Guastella, Anthony R; Michelhaugh, Sharon K; Klinger, Neil V et al. (2018) Investigation of the aryl hydrocarbon receptor and the intrinsic tumoral component of the kynurenine pathway of tryptophan metabolism in primary brain tumors. J Neurooncol 139:239-249
Li, Feng; Wang, Yongli; Li, Dapeng et al. (2018) Perspectives on the recent developments with green tea polyphenols in drug discovery. Expert Opin Drug Discov 13:643-660
Ramseyer, Vanesa D; Kimler, Victoria A; Granneman, James G (2018) Vacuolar protein sorting 13C is a novel lipid droplet protein that inhibits lipolysis in brown adipocytes. Mol Metab 7:57-70
Healy, Mark A; Morris, Arden M; Abrahamse, Paul et al. (2018) The accuracy of chemotherapy ascertainment among colorectal cancer patients in the surveillance, epidemiology, and end results registry program. BMC Cancer 18:481
Lacher, Sarah E; Alazizi, Adnan; Wang, Xuting et al. (2018) A hypermorphic antioxidant response element is associated with increased MS4A6A expression and Alzheimer's disease. Redox Biol 14:686-693
Alsaab, Hashem O; Sau, Samaresh; Alzhrani, Rami M et al. (2018) Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophages. Biomaterials 183:280-294
Chammaa, May; Malysa, Agnes; Redondo, Carlos et al. (2018) RUMI is a novel negative prognostic marker and therapeutic target in non-small-cell lung cancer. J Cell Physiol 233:9548-9562

Showing the most recent 10 out of 826 publications